Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Haleon PLC ( (GB:HLN) ) has issued an update.
Haleon PLC announced that as of September 30, 2025, it has issued a total of 8,952,353,648 ordinary shares, with 44,400,783 held as treasury shares. This results in 8,907,952,865 shares with voting rights, which shareholders and others with notification obligations should use as the denominator for calculating their interest in the company. This update is crucial for stakeholders to comply with the FCA’s Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £3.80 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.
Haleon PLC’s overall stock score reflects a strong financial foundation with robust profitability and cash flow management. However, technical indicators and valuation suggest a more cautious outlook. The earnings call highlighted regional strengths but also significant challenges in North America, impacting the overall sentiment. The absence of notable corporate events leaves the focus on financial and operational performance.
To see Spark’s full report on GB:HLN stock, click here.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company’s product portfolio includes Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Haleon is known for its trusted brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.
Average Trading Volume: 20,248,265
Technical Sentiment Signal: Sell
Current Market Cap: £29.45B
See more data about HLN stock on TipRanks’ Stock Analysis page.